MIRA INFORM REPORT

 

 

Report Date :

06.11.2013

 

IDENTIFICATION DETAILS

 

Name :

MACLEODS PHARMACEUTICALS LIMITED

 

 

Formerly Known As :

MACLEODS PHARMACEUTICALS PRIVATE LIMITED

 

 

Registered Office :

304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai – 400 059, Maharashtra

 

 

Country :

India

 

 

Financials (as on) :

31.03.2012

 

 

Date of Incorporation :

05.06.1989

 

 

Com. Reg. No.:

11-052049

 

 

Capital Investment / Paid-up Capital :

Rs.199.607 Millions

 

 

CIN No.:

[Company Identification No.]

U24239MH1989PLC052049

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

MUMM19656A

 

 

PAN No.:

[Permanent Account No.]

AAACM4100C

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

Manufacturer and Exporter of Pharmaceuticals and related activities including research.

 

 

No. of Employees :

5000 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

A (62)

 

RATING

STATUS

PROPOSED CREDIT LINE

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

Fairly Large

 

Maximum Credit Limit :

USD 36023000

 

 

Status :

Good

 

 

Payment Behaviour :

Regular

 

 

Litigation :

Clear

 

 

Comments :

Subject is a well-established and reputed company having a fine track record. Financial position of the company appears to be sound. Trade relations are reported as fair. Business is active. Payments are reported to be regular and as per commitments.

 

The company can be considered good for normal business dealings at usual trade terms and conditions.

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

India’s current account deficit or CAD in April-June widened to 4.9 % of gross domestic product. High imports of gold and oil led to a worsening of the trade deficit, resulting in CAD jumping to $ 21.8 billion to the latest quarter from $ 16.9 billion in the corresponding quarter of the previous financial year. The government aims to bring down CAD to 3.7 % or $ 70 billion, in 2013/14, from 4.8 % or $ 88.2 billion in 2012/13.

 

The finance ministry has started preparations for Budget 2014/15. With general elections scheduled to be held by May next year, there will only be an interim budget. The new government will present the fiscal Budget.

 

The Supreme Court has barred clinical trials for new drugs till a monitoring mechanism is put in place to protect the lives of people on which the drugs are tested.

 

Mumbai has been named the world’s second most honest city according to a survey on 15 cities worldwide by Readers’ Digest magazine. Finnish capital Helsinki bagged the top spot for the world’s most honest city while Lisbon, the capital of Portugal, proved to be the least honest.  The survey put hundreds of people to test in four continents to find out just how honest they were by dropping wallets and seeing how many would be returned.

 

3.7 % Growth of the core sector in August, a seven month high. This takes the overall growth in April-August this year to 2.3 % compared with 6.3 % in the corresponding period next financial year.

 

$19 million Estimated average spending by companies across the globe including India, on social media this year, according to a global study by information technology major Tata Consultancy Services. This will rise to $ 24 million in 2015.

 

Rising inflation, fewer employment avenues and dwindling earnings are taking a toll on the spending capacity in India. Over 72 % respondents from middle and lower middle income families would be forced to slash their Diwali expenditure by 40 % and on average spend nearly 25 % of their monthly salary on Diwali, according to a survey by Assochem.

 

Analysts believe the shutdown of the US government would have limited impact in sectors such as IT or tourism that are dependent on Visa clearances.

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CRISIL

Rating

Short Term Rating A1+ (Placed on notice of Withdrawal)

Rating Explanation

Very strong degree of safety. It carry lowest credit risk.

Date

13.09.2013

 

NOTE: Notice of withdrawal for a period of 180 days on Macleods request. The ratings shall be withdrawn at the end of the notice period.

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

LOCATIONS

 

Registered Office :

304, Atlanta Arcade, Marol Church Road, Andheri (East), Mumbai – 400 059, Maharashtra, India

Tel. No.:

91-22-66762800/ 56762800

Fax No.:

91-22-28266229/ 29256599

E-Mail :

macleods@vsnl.com

investors@macleodspharma.com

exports@macleodspharma.com

customercare@macleodspharma.com

sagarwal@macleodspharma.com

Website :

http://www.macleodspharma.com 

Location :

Owned

 

 

Factory 1 :

Plot No. 1 and 2, Mahim Road, Near Kuldeep Hotel, Palghar (West), District Thane – 401 404, Maharashtra, India

 

 

Factory 2 :

Village: Theda, Kharuni- Lodimajra, Thehesil- Nalagarh, Baddi Industrial Estate Area, District: Solan, Himachal Pradesh, India

 

 

Factory 3 / Daman- Premier- Unit II :

Plot no. 25-27,  Survey No. 366, Premier Industrial Estate, Kachigam, Daman – 396 320, Daman and Diu, India

 

 

Factory 4 / Daman- Kabra- Unit III :

Plot No. 367/ 7, Kabra Industrial Estate, Kachigam, Daman – 396 210, Daman and Diu, India

 

 

Factory 5  :

Plot No.2209, GIDC Sarigam, District: Valsad, Gujarat, India

 

 

DIRECTORS

 

AS ON 28.09.2012

 

Name :

Mr. Banwarilal Murildhar Bawri

Designation :

Managing Director

Address :

5, Vinayak Heights, Upper Govind Nagar, Malad (East), Mumbai – 400 097, Maharashtra, India

Date of Birth/Age :

02.04.1953

Qualification :

D. Pharm

Date of Appointment :

01.04.2010

DIN No.:

00017795

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U85195MH1987PTC045607

MECLEODS LABORATORIES PRIVATE LIMITED

Director

16-12-87

16-12-87

Active

NO

2

U24239MH1989PLC052049

MACLEODS PHARMACEUTICALS LIMITED

Managing director

01-04-10

05-06-89

Active

NO

3

U29140MH1975PTC018072

EAST AND WEST CLOTHING PRIVATE LIMITED

Director

25-04-04

25-04-04

Active

NO

 

 

Name :

Mr. Rajendra Murlidhar Agarwal

Designation :

Managing Director

Address :

5, Vinayak Heights, Upper Govind Nagar, Malad (East), Mumbai – 400 097, Maharashtra, India

Date of Birth/Age :

25.02.1959

Qualification :

M.B.B.S.

Date of Appointment :

01.04.2010

DIN No.:

00034224

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U85195MH1987PTC045607

MECLEODS LABORATORIES PRIVATE LIMITED

Director

16-12-87

16-12-87

Active

NO

2

U24239MH1989PLC052049

MACLEODS PHARMACEUTICALS LIMITED

Managing director

01-04-10

05-06-89

Active

NO

3

U29140MH1975PTC018072

EAST AND WEST CLOTHING PRIVATE LIMITED

Director

25-04-04

25-04-04

Active

NO

 

 

Name :

Mr. Girdharilal Murlidhar Bawri

Designation :

Director

Address :

5, Vinayak Heights, Upper Govind Nagar, Malad (East), Mumbai – 400 097, Maharashtra, India

Date of Birth/Age :

03.08.1947

Qualification :

B. Com / D. Pharma

Date of Appointment :

22.05.1990

DIN No.:

00034197

 

 

Name :

Mr. Vimal Manekchand Kothari

Designation :

Director

Address :

132, Avanti Apartment, Senapati Bapat Marg, Dadar (West), Mumbai-40028, Maharashtra, India

Date of Birth/Age :

28.06.1940

Qualification :

M.Com / LLB / FICWA

Date of Appointment :

27.03.2006

DIN No.:

00056003

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24119MH1986PLC135077

KASYAP SWEETNERS LIMITED

Director

06-03-97

06-03-97

Active

NO

2

U24239MH1989PLC052049

MACLEODS PHARMACEUTICALS LIMITED

Director

27-03-06

27-03-06

Active

NO

3

U93000MH2013NPL241775

LOKASHRAYA FOUNDATION

Director

08-04-13

08-04-13

Active

NO

4

U55101MH2008PLC177941

WEST LEISURE RESORTS LIMITED

Director

19-07-13

19-07-13

Active

NO

 

 

Name :

Mr. Navrang Ladhuram Tibrewal

Designation :

Director

Address :

Plot No. A, Schemeno 8, Gandhipath, Queens Road, Jaipur – 302 021, Rajashtra, India 

Date of Birth/Age :

17.01.1937

Qualification :

LLM

Date of Appointment :

27.03.2006

DIN No.:

00030151

Other Directorship:

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Date of cessation

Company/ LLP Status

Defaulting status

1

L17120AP1962PLC000923

SURYA LAKSHMI COTTON MILLS LIMITED

Director

30-07-01

30-07-01

-

Active

NO

2

U67110RJ1983PLC002861

JAIPUR STOCK EXCHANGE LTD

Director

12-04-02

12-04-02

31-08-13

Active

NO

3

U67120RJ2000PLC016337

JSEL SECURITIES LIMITED

Director

30-05-03

30-05-03

22-03-04

Active

NO

4

U24239MH1989PLC052049

MACLEODS PHARMACEUTICALS LIMITED

Director

27-03-06

27-03-06

-

Active

NO

5

U17110AP1994PLC018745

SURYAKIRAN INTERNATIONAL LIMITED

Director

16-10-10

16-10-10

-

Active

NO

 

 

KEY EXECUTIVES

 

Name :

Mrs. Suvarna Dadabhau Gholap

Designation :

Secretary

Address :

103-A, Building No.26, Tilak Nagar, Chembur, Mumbai – 400 089, Maharashtra, India

Date of Birth/Age :

15.07.1982

Date of Appointment :

01.03.2011

PAN No.:

ANJPG7538B

 

 

Name :

Mr. Suresh

Designation :

Account Manager

 

 

MAJOR SHAREHOLDERS

 

AS ON 28.09.2012

 

Names of Shareholders

 

No. of Shares

Percentage

Banwarilal Murildhar Bawri

6044160

30.28

Ajay Agarwal

4255800

21.32

Anju Agarwal

3256200

16.31

Rajendra Murlidhar Agarwal

3084360

15.45

Girdharilal Murlidhar Bawri

2235360

11.2

Sudha Bawri

380400

1.91

Anushree Agarwal

229200

1.15

Ruchi Agarwal

192840

0.97

Taradevi Bawri

162000

0.81

Rajendra Murlidhar Agarwal HUF

120000

0.6

Vijay Agarwal

360

0.00

 

 

 

Total

19960680

100.00

 

 

Equity Share Break up (Percentage of Total Equity)

 

AS ON 28.09.2012

 

Category

Percentage

Directors or relatives of Directors

100.00

 

 

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer and Exporter of Pharmaceuticals and related activities including research.

 

 

Products :

Item Code No.

Product Description

30042034

Ofloxacin USP 200mg Tablet

30049072

Amlodipine besylate equiv. To Amlod 5mg/Aten 50mg

30049057

Deflazacort 6mg Tablet

30049072

Amlodipine besylate equiv. To Amlodipine 5mg

30043912

Prednisolone dispersible Tablet 10mg

30042092

Rifa225/Iso 150/Etha 450/Pyra 750 Tablet

30049057

Levofloxacin 5mg Tablet

30043912

Prednisolone dispersible Tablet 5mg

30043912

Prednisolone dispersible Tablet 20mg

·         Drugs

·         Pharmaceuticals

·         Alkalis

·         Acids

·         Essences

·         Petrochemicals

·         Chemicals

 

 

GENERAL INFORMATION

 

No. of Employees :

5000 (Approximately)

 

 

Bankers :

·         CITI Bank N.A., Commercial Banking Group, Bandra Kurla Complex, Mumbai – 400 051, Maharashtra, India

·         State Bank of India, N.G.N. Vaidya Marg, Mumbai – 400 023, Maharashtra, India

·         ICICI Bank Limited, 1st Floor, Ganesh Darshan Building, L.T. Road, Opposite Shri Sagar Hotel, Borivali West – 400 092, Maharashtra, India

 

 

Facilities :

SECURED LOANS

31.03.2012

Rs. In Millions

31.03.2011

Rs. In Millions

Short Term Borrowings

 

 

Working Capital Loans from Banks

1474.661

749.624

 

 

 

Total

1474.661

749.624

 

NOTES:

Working Capital is secured by first charge on Inventories and Debtors of the Company.

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

Bansal Bansal and Company

Chartered Accountant

Address :

120 Building No.6, Mittal Idustrial Estate, Mumbai – 400 059, Maharashtra, India

Tel. No.:

91-22-28507815/66923607/28507816

Fax No.:

91-22-28507816

E-Mail :

mail@bansalbansal.com

PAN No.:

AABFB5224E

 

 

Subsidiaries :

·         East and West Clothing Private Limited 

[CIN No.: U29140MH1975PTC018072]

·         Macleods Pharma UK Limited, United Kingdom

·         Macleods Pharmaceuticals SA (PTY) Limited, South Africa

·         Macleods Pharmaceuticals Limited, Peru S.A.C.

·         Macleods Pharmaceuticals Limited, Ukraine

·         Macleods Pharma USA, INC., United States

 

 

Associates :

·         Macleods Laboratories Private Limited, India

 

 

Enterprises which are owned, or have significant influence of or are partners with Key management Personnel and their relatives :

·         Jindal Enterprises

·         Medico Distributors

·         Shree Adinath Enterprises

·         Oxalis Labs

·         Macleods Tashkent, Uzbek

·         Lance Financial Consultants Private Limitedwe

 

 

 

 

CAPITAL STRUCTURE

 

AS ON 28.09.2012

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

25000000

Equity Shares

Rs. 10/- each

Rs.250.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

19960680

Equity Shares

Rs. 10/- each

Rs.199.607 Millions

 

 

 

 

 


FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

 

31.03.2012

31.03.2011

I.        EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

 

199.607

199.607

(b) Reserves & Surplus

 

8806.163

6318.052

(c) Money received against share warrants

 

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

 

0.000

0.000

Total Shareholders’ Funds (1) + (2)

 

9005.770

6517.659

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

 

19.508

20.312

(b) Deferred tax liabilities (Net)

 

274.074

264.294

(c) Other long term liabilities

 

79.450

79.304

(d) long-term provisions

 

40.654

28.386

Total Non-current Liabilities (3)

 

413.686

392.296

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

 

1480.124

754.270

(b) Trade payables

 

1259.888

1848.523

(c) Other current liabilities

 

686.569

755.933

(d) Short-term provisions

 

4.694

186.017

Total Current Liabilities (4)

 

3431.275

3544.743

 

 

 

 

TOTAL

 

12850.731

10454.698

 

 

 

 

II.      ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

 

2666.021

2421.561

(ii) Intangible Assets

 

2.279

1.188

(iii) Capital work-in-progress

 

123.775

87.115

(iv) Intangible assets under development

 

0.000

0.000

(b) Non-current Investments

 

99.459

92.951

(c) Deferred tax assets (net)

 

0.000

0.000

(d)  Long-term Loan and Advances

 

1179.668

744.446

(e) Other Non-current assets

 

67.479

1658.918

Total Non-Current Assets

 

4138.681

5006.179

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

 

0.000

0.000

(b) Inventories

 

2450.497

2705.776

(c) Trade receivables

 

2575.356

1841.994

(d) Cash and cash equivalents

 

3080.621

474.823

(e) Short-term loans and advances

 

375.773

267.881

(f) Other current assets

 

229.803

158.045

Total Current Assets

 

8712.050

5448.519

 

 

 

 

TOTAL

 

12850.731

10454.698

 

 

SOURCES OF FUNDS

 

 

 

31.03.2010

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

 

 

199.607

2] Share Application Money

 

 

0.000

3] Reserves & Surplus

 

 

4401.450

4] (Accumulated Losses)

 

 

0.000

NETWORTH

 

 

4601.057

LOAN FUNDS

 

 

 

1] Secured Loans

 

 

974.077

2] Unsecured Loans

 

 

71.654

TOTAL BORROWING

 

 

1045.731

DEFERRED TAX LIABILITIES

 

 

0.000

 

 

 

 

TOTAL

 

 

5646.788

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

 

 

1907.111

Capital work-in-progress

 

 

26.177

 

 

 

 

INVESTMENT

 

 

580.281

DEFERRED TAX ASSETS

 

 

96.753

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

 

 

1609.672

 

Sundry Debtors

 

 

967.449

 

Cash & Bank Balances

 

 

1669.811

 

Other Current Assets

 

 

0.000

 

Loans & Advances

 

 

783.880

Total Current Assets

 

 

5030.812

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

 

 

1411.551

 

Other Current Liabilities

 

 

30.949

 

Provisions

 

 

551.845

Total Current Liabilities

 

 

1994.345

Net Current Assets

 

 

3036.467

 

 

 

 

MISCELLANEOUS EXPENSES

 

 

0.000

 

 

 

 

TOTAL

 

 

5646.789

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2012

31.03.2011

31.03.2010

 

SALES

 

 

 

 

 

Income

18253.630

14123.962

8905.032

 

 

Other Income

239.016

156.741

218.273

 

 

TOTAL                                         (A)

18492.646

14280.703

9123.305

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Material Consumed

6049.579

5617.835

 

 

Purchase of stock-in-trade

1857.542

1313.879

 

 

 

Changes in Inventories of finished goods, work-in-progress and stock-in-trade

98.450

(695.473)

 

 

 

Employee benefit Expenses

2460.840

1834.619

 

 

 

Other Expenses

4860.368

3697.095

 

 

 

TOTAL                                         (B)

15326.779

11767.955

7485.363

 

 

 

 

 

Less

PROFIT/(LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

3165.867

2512.748

1637.942

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

72.873

21.019

37.858

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                (E)

3092.994

2491.729

1600.084

 

 

 

 

 

Less

DEPRECIATION/ AMORTISATION                     (F)

227.393

193.584

195.301

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX (E-F)                   (G)     

2865.601

2298.145

1404.783

 

 

 

 

 

Less

TAX                                                                  (H)

145.501

149.402

72.139

 

 

 

 

 

 

PROFIT/(LOSS) AFTER TAX (G-H)                    (I)

2720.100

2148.743

1332.644

 

 

 

 

 

Add

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

5874.193

4192.600

2956.585

 

 

 

 

 

Less

APPROPRIATIONS

 

 

 

 

 

Transfer to General Reserve

275.000

235.000

50.000

 

 

Dividend

199.610

199.610

39.921

 

 

Tax on Dividend

32.380

32.540

6.708

 

BALANCE CARRIED TO THE B/S

8087.310

5874.193

4192.600

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

 

 

 

 

 

FOB Value of Manufactured Goods Exported

3376.106

3204.059

1752.335

 

TOTAL EARNINGS

3376.106

3204.059

1752.335

 

 

 

 

 

 

IMPORTS

 

 

 

 

 

Raw Materials

1908.988

1581.995

 

 

 

Stores & Spares

14.791

11.667

 

 

 

Capital Goods

78.768

133.212

 

 

TOTAL IMPORTS

2002.547

1726.874

NA

 

 

 

 

 

 

Earnings Per Share (Rs.)

136.27

107.65

66.8

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2012

31.03.2011

31.03.2010

PAT / Total Income

(%)

14.71

15.05

14.61

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

15.70

16.27

15.78

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

25.18

29.20

20.25

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.32

0.35

0.31

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

0.17

0.12

0.23

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

2.54

1.54

2.52

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

Yes

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

----------

22]

Litigations that the firm / promoter involved in

----------

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------

26]

Buyer visit details

----------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

 

 

UNSECURED LOANS:

 

Particulars

31.03.2012

Rs. In Millions

31.03.2011

Rs. In Millions

Long Term Borrowings

 

 

From Members

19.508

20.312

Short Term Borrowings

 

 

From Members

5.463

4.646

 

 

 

Total

24.971

24.958

 

 

INDEX OF CHARGE:

 

Sr. No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

Charge Holder

Address

Service Request Number (SRN)

1

10449202

19/09/2013

15,460,000.00

ICICI BANK LIMITED

1ST FLOOR, GANESH DARSHAN BUILDING, L. T. ROAD, OPP. SHRI SAGAR HOTEL, BORIVALI WEST – 400 092, MAHARASHTRA, INDIA

B85072510

2

10449114

19/09/2013

17,850,000.00

ICICI BANK LIMITED

1ST FLOOR, GANESH DARSHAN BUILDING, L. T. ROAD, OPP. SHRI SAGAR HOTEL, BORIVALI WEST – 400 092, MAHARASHTRA, INDIA

B85015006

3

10449057

19/09/2013

22,160,000.00

ICICI BANK LIMITED

1ST FLOOR, GANESH DARSHAN BUILDING, L. T. ROAD, OPP. SHRI SAGAR HOTEL, BORIVALI WEST – 400 092, MAHARASHTRA, INDIA

B84988856

4

10449059

19/09/2013

22,160,000.00

ICICI BANK LIMITED

1ST FLOOR, GANESH DARSHAN BUILDING, L. T. ROAD, OPP. SHRI SAGAR HOTEL, BORIVALI WEST – 400 092, MAHARASHTRA, INDIA

B84990639

5

90224199

18/12/2000 *

2,950,000.00

STATE BANK OF INDIA

MALAD BRANCH, MUMBAI, MAHARASHTRA, INDIA

-

 

* Date of charge modification

 

 

FIXED ASSETS:

 

·         Land

·         Factory Building

·         Plant and Machinery

·         Vehicles

·         Training

·         Office Equipment

·         Factory Equipments

·         Computers

 

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                              None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.61.79

UK Pound

1

Rs.98.66

Euro

1

Rs.83.42

 

 

INFORMATION DETAILS

 

Report Prepared by :

NKT

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

6

PAID-UP CAPITAL

1~10

7

OPERATING SCALE

1~10

7

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

7

--PROFITABILIRY

1~10

7

--LIQUIDITY

1~10

7

--LEVERAGE

1~10

7

--RESERVES

1~10

7

--CREDIT LINES

1~10

7

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

YES

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

 

 

 

TOTAL

 

62

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.